ANI Pharmaceuticals, Inc. Profile
Industry
Drug Manufacturers - Specialty & GenericSector
HealthcareNumber of Employees
642ANI Pharmaceuticals's Business Model
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
About ANI Pharmaceuticals
Website: https://www.anipharmaceuticals.com
CEO (Chief Executive Officer): Mr. Stephen P. Carey
IPO date: 2000-05-05
Contact
Country: US
Address: 210 Main Street West
City: Baudette
State: MN
Phone: 218 634 3500
Zip Code: 56623
Other
CIK: 0001023024
ISIN: US00182C1036
CUSIP: 00182C103
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
